Injectable Drug Delivery Market is expected to reach $43.3 Billion by 2017
Dallas, Texas: The Injectables Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017,analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and Rest of the World.
Browse 155 market data tables with 27 figures spread through 368 pages and in-depth TOC on Injectables Drug Delivery by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] Market - Global Forecasts to 2017
Early buyers will receive 10% customization on reports.
This report studies the global injectable drug delivery technologies market over the forecast period of 2012 to 2017.
The global injectable drug delivery technologies market was valued at $22.5 billion in 2012; it is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. The injectable drug delivery technologies market is broadly categorized into two major segments, namely, devices technologies and formulation technologies. Based on product, the injectable drug delivery devices technologies market is further categorized into conventional injection devices, self injection devices, and others (microneedles, nanoneedles and blunt needle injections), while injectable drug delivery formulation technologies market is categorized into conventional drug delivery formulations and novel drug delivery formulations. Conventional injection devices segment accounted for the largest shareof the overall injectable drug delivery technologies market in 2012.
In addition, the market is segmented on the basis of its therapeutic applications such as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilson’s disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of 50.0% of the global injectable drug delivery technologies market in 2012; it is expected to grow at a CAGR of 13.9% to reach $21.6 billion by 2017. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. As per The American Autoimmune Related Diseases Association, 50 million Americans or 20% of the population or one in five people, are living and managing with auto immune diseases during the year 2013.
The major geographic markets covered in this report are North America, Europe, Asia-Pacific, and RoW.North America dominates the market, followed by Europe. However,Asian and Latin American countries represent the fastest growing markets due to growing number of cancer and diabetes incidences, and improving patent compliance.
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304 Preston Road, Suite 800,
Dallas, TX 75252
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.